Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.26M | 5.04M | 5.33M | 9.96M | 6.78M | 8.03M |
Gross Profit | 2.08M | 2.08M | 2.03M | 154.00K | -1.93M | 2.83M |
EBITDA | -5.47M | -7.50M | -13.58M | -13.65M | -23.27M | -5.44M |
Net Income | -2.02M | -7.04M | -13.98M | -15.61M | -16.13M | -6.03M |
Balance Sheet | ||||||
Total Assets | 12.99M | 13.52M | 19.70M | 28.92M | 43.92M | 47.35M |
Cash, Cash Equivalents and Short-Term Investments | 3.16M | 4.24M | 11.64M | 20.64M | 28.68M | 25.67M |
Total Debt | 21.00K | 155.00K | 1.01M | 2.02M | 3.29M | 9.35M |
Total Liabilities | 4.08M | 7.29M | 7.00M | 8.02M | 12.72M | 18.80M |
Stockholders Equity | 8.90M | 6.22M | 12.84M | 21.03M | 31.09M | 27.73M |
Cash Flow | ||||||
Free Cash Flow | -8.01M | -9.64M | -15.30M | -14.05M | -26.88M | -32.55M |
Operating Cash Flow | -8.01M | -9.63M | -15.29M | -13.98M | -25.87M | -30.22M |
Investing Cash Flow | 7.84M | 7.34M | -4.34M | 1.42M | 16.61M | 17.28M |
Financing Cash Flow | 9.00K | 9.00K | 5.51M | 4.52M | 21.90M | 20.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $20.49B | 14.78 | -2.98% | 3.11% | 1.86% | -5.76% | |
62 Neutral | $181.23M | 193.48 | -3.00% | ― | -13.98% | -403.56% | |
55 Neutral | $153.53M | ― | -42.97% | 0.78% | -9.57% | -3226.39% | |
54 Neutral | $135.25M | ― | -973.22% | ― | 57.83% | 40.94% | |
52 Neutral | $4.65M | ― | -87.18% | ― | 1.50% | -8.01% | |
44 Neutral | $170.80M | ― | -69.68% | ― | ― | ― | |
41 Neutral | $8.47M | 2.75 | ― | -21.82% | -104.92% |
On August 26, 2025, Arcadia Biosciences‘ CFO, Mark Kawakami, announced his resignation effective September 12, 2025, with no disagreements cited as the reason. Thomas J. Schaefer, the company’s President and CEO, will assume the role of Interim CFO. Additionally, Arcadia is involved in a proposed all-stock transaction with Roosevelt Resources, with plans to issue shares in exchange for Roosevelt’s equity interests, pending regulatory approvals.